Overview

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the response and safety in subjects receiving the drugs lenalidomide and azacitidine when each drug is given by itself and when the drugs are taken together. This study is open for patients with relapsed or refractory follicular or marginal zone lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Celgene
Treatments:
Azacitidine
Lenalidomide
Thalidomide